Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

An investigation has found at least 74 complaints have been made to hospital managers across England in the past 12 months.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

The rise of GLP-1 drugs is a reminder that we must move beyond the simple equation of thinness as health and value. These ...

Morrisons Clinic, the supermarket's online prescription service, has launched the weight-loss jab which has been dubbed 'the ...

A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast cancer caused by obesity.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.